The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives?
In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such benefits within five years.
“Five years after the initial accelerated approval, you should have a definitive answer,” said Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania who was not involved in the research. “Thousands of people are getting those drugs. That seems a mistake if we don’t know whether they work or not.”
The program was created in 1992 to speed access to HIV drugs. Today, 85% of accelerated approvals go to cancer drugs.
It allows the FDA to grant early approval to drugs that show promising initial results for treating debilitating or fatal diseases. In exchange, drug companies are expected to do rigorous testing and produce better evidence before gaining full approval.
The EU's executive decides to end legal standoff with Poland over democracy concerns
Chinese researchers develop immunotherapeutic agent for colon cancer
In North Macedonia, two inmates walked out of hospital. Now, police are accused of helping them
One Extraordinary Photo: An AP photographer explains how he captured the total eclipse
José Ramírez breaks Larry Doby’s team record for go
Beijing International Film Festival to feature French film week
The Philippine president says he won't give US access to more local military bases
Bodies of foreign aid workers transferred to Egypt from Gaza
José Ramírez breaks Larry Doby’s team record for go
One Extraordinary Photo: An AP photographer explains how he captured the total eclipse